Peplin releases Quarterly Report
2008-12-02 10:50:00+10:00
Peplin [ASX:PLI] has published it's Quarterly Report to the ASX. making a formal announcement entitled 'Form 10-Q - Quarterly Report' published on Tuesday 02 December 2008. The report begins ... ASX RELEASE Form 10-Q Quarterly Report EMERYVILLE, United States and BRISBANE, Australia, 2 December 2008: Peplin, Inc. ... Peplin has issued similar announcements one time before, most recently about 0 minutes ago on Friday 31 October 2008. [Notice Type: Company Reports - Quarterly]
2008-12-02 10:50:00+10:00
Peplin [ASX:PLI] has published it's Quarterly Report to the ASX. making a formal announcement entitled 'Form 10-Q - Quarterly Report' published on Tuesday 02 December 2008. The report begins ... ASX RELEASE Form 10-Q Quarterly Report EMERYVILLE, United States and BRISBANE, Australia, 2 December 2008: Peplin, Inc. ... Peplin has issued similar announcements one time before, most recently about 0 minutes ago on Friday 31 October 2008. [Notice Type: Company Reports - Quarterly]
Form 10-Q - Quarterly Report
Tuesday 02 Dec 2008
ASX RELEASE Form 10-Q – Quarterly Report
EMERYVILLE, United States and BRISBANE, Australia, 2 December 2008: Peplin, Inc. (ASX:PLI) filed a Form 10-Q quarterly report with the US Securities and Exchange Commission on 1 December 2008. The report includes unaudited financial statements for the three months ended 30 September 2008. A copy of the Form 10-Q is attached.
Further information: Tom Wiggans Chief Executive Officer Tel: +1-510-653 9700 tom.wiggans@peplin.com
HU UH
Media: Camilla Myers Hill & Knowlton Tel: 02-9286 1248 mailto:cmyers@hillandknowlton.com.au
HU U
ABOUT PEPLIN Peplin is a development stage specialty pharmaceutical company focused on advancing and commercializing innovative medical dermatology products. Peplin is currently developing PEP005 (ingenol mebutate), which is the first in a new class of compounds and which is derived from the sap of Euphorbia peplus, or E. peplus, a rapidly growing, readily available plant commonly referred to as petty spurge or radium weed. E. peplus has a long history of traditional use for a variety of conditions, including the topical selftreatment of various skin disorders, including skin cancer and pre-cancerous skin lesions. Peplin’s lead product candidate is a patient-applied topical gel containing ingenol mebutate, a compound the use of which Peplin has patented for the treatment of actinic (solar) keratosis, or AK. This product candidate is currently in Phase III clinical trials (trial known as REGION-I) and is referred to as PEP005 (ingenol mebutate) Gel.
FORWARD LOOKING STATEMENTS This press release contains “forward-looking statements” as defined under U.S. federal securities laws, including, but not limited to, Peplin’s clinical development plan referred to herein. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward looking
S:\Corporate\Secretariat\ASX\Announcements\2008-09\081202 ASX release 10Q.doc6475 Christie Avenue, Emeryville, CA 94608, USA Tel: +-653 9700 Fax: +-653 9704 Level 2, Brisbane Portal, 1 Breakfast Creek Road, Newstead, QLD, 4006, Australia Tel: +61-7-3250 1200 Fax: +61-7-3250 1299 www.peplin.com
statements are based on management's current, preliminary expectations and actual results could differ materially as a result of various risks and uncertainties, including, but not limited to, delays in the completion of clinical trials resulting from, among other things, ambiguous or negative interim results, unforeseen safety issues, failure to conduct the clinical trials in accordance with regulatory requirements or clinical protocols, suspension or termination of a clinical trial by the FDA or other regulatory authorities, lack of adequate funding to continue a clinical trial and other important factors disclosed from time to time in Peplin’s disclosures to the ASX. Forward-looking statements speak only as of the date they were made. No undue reliance should be placed on any forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
S:\Corporate\Secretariat\ASX\Announcements\2008-09\081202 ASX release 10Q.docPg
2/2
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-53410
Peplin, Inc.
(Exact name of registrant as specified in its charter) Delaware
(State or Other Jurisdiction of Incorporation or Organization)
26-0641830
(I.R.S. Employer Identification No.)
6475 Christie Avenue, Emeryville, California
(Address of Principal Executive Offices)
94608
(Zip Code)
(510) 653-9700
(Registrant’s Telephone Number, including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company
Yes
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). No As of November 24, 2008, there were 15,141,121 shares of common stock outstanding.
PEPLIN, INC. FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2008 INDEX PART I — FINANCIAL INFORMATION Item 1. Financial Statements Condensed Consolidated Balance Sheets — September 30, 2008 (unaudited) and June 30, 2008 Condensed Consolidated Statements of Operations (unaudited) — Three Months Ended September 30, 2008 and September 30, 2007 Condensed Consolidated Statements of Cash Flows (unaudited) — Three Months Ended September 30, 2008 and September 30, 2007 Notes to Consolidated Financial Statements (Unaudited) Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 3. Quantitative and Qualitative Disclosure About Market Risk Item 4. Controls and Procedures Item 4T. Controls and Procedures PART II — OTHER INFORMATION Item 1. Legal Proceedings Item 1A. Risk Factors Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Item 3. Defaults Upon Senior Securities Item 4. Submissions of Matters to a Vote of Security Holders Item 5. Other Information Item 6. Exhibits Signatures i 1 1 1 3 4 6 16 24 24 24 25 25 25 25 25 25 26 27 28
PART I — FINANCIAL INFORMATION Item 1. Financial Statements Peplin, Inc. Condensed Consolidated Balance Sheets
September 30, 2008 (unaudited) June 30, 2008
Assets: Current assets: Cash and cash equivalents Grant income receivable Interest receivable Prepaid expenses Deferred costs Other current assets Total current assets Non-current assets: Restricted cash Lease deposits Plant and equipment – net Other non-current assets Total non-current assets Total assets Liabilities and stockholders’ equity: Current ...
Tuesday 02 Dec 2008
ASX RELEASE Form 10-Q – Quarterly Report
EMERYVILLE, United States and BRISBANE, Australia, 2 December 2008: Peplin, Inc. (ASX:PLI) filed a Form 10-Q quarterly report with the US Securities and Exchange Commission on 1 December 2008. The report includes unaudited financial statements for the three months ended 30 September 2008. A copy of the Form 10-Q is attached.
Further information: Tom Wiggans Chief Executive Officer Tel: +1-510-653 9700 tom.wiggans@peplin.com
HU UH
Media: Camilla Myers Hill & Knowlton Tel: 02-9286 1248 mailto:cmyers@hillandknowlton.com.au
HU U
ABOUT PEPLIN Peplin is a development stage specialty pharmaceutical company focused on advancing and commercializing innovative medical dermatology products. Peplin is currently developing PEP005 (ingenol mebutate), which is the first in a new class of compounds and which is derived from the sap of Euphorbia peplus, or E. peplus, a rapidly growing, readily available plant commonly referred to as petty spurge or radium weed. E. peplus has a long history of traditional use for a variety of conditions, including the topical selftreatment of various skin disorders, including skin cancer and pre-cancerous skin lesions. Peplin’s lead product candidate is a patient-applied topical gel containing ingenol mebutate, a compound the use of which Peplin has patented for the treatment of actinic (solar) keratosis, or AK. This product candidate is currently in Phase III clinical trials (trial known as REGION-I) and is referred to as PEP005 (ingenol mebutate) Gel.
FORWARD LOOKING STATEMENTS This press release contains “forward-looking statements” as defined under U.S. federal securities laws, including, but not limited to, Peplin’s clinical development plan referred to herein. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward looking
S:\Corporate\Secretariat\ASX\Announcements\2008-09\081202 ASX release 10Q.doc6475 Christie Avenue, Emeryville, CA 94608, USA Tel: +-653 9700 Fax: +-653 9704 Level 2, Brisbane Portal, 1 Breakfast Creek Road, Newstead, QLD, 4006, Australia Tel: +61-7-3250 1200 Fax: +61-7-3250 1299 www.peplin.com
statements are based on management's current, preliminary expectations and actual results could differ materially as a result of various risks and uncertainties, including, but not limited to, delays in the completion of clinical trials resulting from, among other things, ambiguous or negative interim results, unforeseen safety issues, failure to conduct the clinical trials in accordance with regulatory requirements or clinical protocols, suspension or termination of a clinical trial by the FDA or other regulatory authorities, lack of adequate funding to continue a clinical trial and other important factors disclosed from time to time in Peplin’s disclosures to the ASX. Forward-looking statements speak only as of the date they were made. No undue reliance should be placed on any forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
S:\Corporate\Secretariat\ASX\Announcements\2008-09\081202 ASX release 10Q.docPg
2/2
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-53410
Peplin, Inc.
(Exact name of registrant as specified in its charter) Delaware
(State or Other Jurisdiction of Incorporation or Organization)
26-0641830
(I.R.S. Employer Identification No.)
6475 Christie Avenue, Emeryville, California
(Address of Principal Executive Offices)
94608
(Zip Code)
(510) 653-9700
(Registrant’s Telephone Number, including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company
Yes
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). No As of November 24, 2008, there were 15,141,121 shares of common stock outstanding.
PEPLIN, INC. FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2008 INDEX PART I — FINANCIAL INFORMATION Item 1. Financial Statements Condensed Consolidated Balance Sheets — September 30, 2008 (unaudited) and June 30, 2008 Condensed Consolidated Statements of Operations (unaudited) — Three Months Ended September 30, 2008 and September 30, 2007 Condensed Consolidated Statements of Cash Flows (unaudited) — Three Months Ended September 30, 2008 and September 30, 2007 Notes to Consolidated Financial Statements (Unaudited) Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 3. Quantitative and Qualitative Disclosure About Market Risk Item 4. Controls and Procedures Item 4T. Controls and Procedures PART II — OTHER INFORMATION Item 1. Legal Proceedings Item 1A. Risk Factors Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Item 3. Defaults Upon Senior Securities Item 4. Submissions of Matters to a Vote of Security Holders Item 5. Other Information Item 6. Exhibits Signatures i 1 1 1 3 4 6 16 24 24 24 25 25 25 25 25 25 26 27 28
PART I — FINANCIAL INFORMATION Item 1. Financial Statements Peplin, Inc. Condensed Consolidated Balance Sheets
September 30, 2008 (unaudited) June 30, 2008
Assets: Current assets: Cash and cash equivalents Grant income receivable Interest receivable Prepaid expenses Deferred costs Other current assets Total current assets Non-current assets: Restricted cash Lease deposits Plant and equipment – net Other non-current assets Total non-current assets Total assets Liabilities and stockholders’ equity: Current ...
